Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · see citing works

Ageing as a risk factor for neurodegenerative disease

Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · see citing works

Stages in the development of Parkinson’s disease-related pathology

Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · see citing works

The Amyloid-β Pathway in Alzheimer’s Disease

Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952 · see citing works

Inflammation and immune dysfunction in Parkinson disease

Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00684-6 · Cited by 1,382 · see citing works

Alzheimer’s disease is type 3 diabetes—Evidence reviewed

de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158 · see citing works

Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study

Kivipelto, M., Ngandu, T., Laatikainen, T. K., Winblad, B. G., Soininen, H. S., & Tuomilehto, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70537-3 · Cited by 1,127 · see citing works

Ageing and neuronal vulnerability

Mattson, M. P., & Magnus, T. (2006) · Nature reviews. Neuroscience · doi:10.1038/nrn1886 · Cited by 1,075 · see citing works

Current and Future Treatments in Alzheimer Disease: An Update

Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · see citing works

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · see citing works

The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017

Deuschl, G., Beghi, E., Fazekas, F., Varga, T., Christoforidi, K., Sipido, E., Bassetti, C. L., Vos, T., & Feigin, V. L. (2020) · The Lancet Public Health · doi:10.1016/s2468-2667(20)30190-0 · Cited by 633 · see citing works

The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion

MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590 · see citing works

Exenatide and the treatment of patients with Parkinson's disease

Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529 · see citing works

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · see citing works

Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential

Henrich, M. T., Oertel, W. H., Surmeier, D. J., & Geibl, F. F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00676-7 · Cited by 435 · see citing works

Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists

Kapadia, R. (2008) · Frontiers in Bioscience · doi:10.2741/2802 · Cited by 433 · see citing works

Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease

Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387 · see citing works

Trial of Lixisenatide in Early Parkinson’s Disease

Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312323 · Cited by 369 · cited 1× · see citing works

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361 · see citing works

Effects of the Insulin Sensitizer Metformin in Alzheimer Disease

Koenig, A. M., Mechanic-Hamilton, D. J., Xie, S. X., Combs, M., Cappola, A. R., Xie, L., Detre, J. A., Wolk, D. A., & Arnold, S. E. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000202 · Cited by 352 · see citing works

Incidence of Parkinson disease in North America

Willis, A. W., Roberts, E., Beck, J. C., Fiske, B., Ross, W., Savica, R., Van Den Eeden, S. K., Tanner, C. M., Marras, C., on behalf of the Parkinson’s Foundation P4 Group, et al. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00410-y · Cited by 341 · see citing works

Insulin Resistance and Neurodegeneration: Progress towards the Development of New Therapeutics for Alzheimer's Disease

de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331 · see citing works

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30173-3 · Cited by 300 · see citing works

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial

(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00144-1 · Cited by 286 · see citing works

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs

Giugliano, D., Scappaticcio, L., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., Ceriello, A., Chiodini, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01366-8 · Cited by 263 · cited 1× · see citing works

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease

Athauda, D. S., Gulyani, S., Karnati, H. K., Li, Y., Tweedie, D., Mustapić, M., Chawla, S., Chowdhury, K., Skene, S. S., Greig, N. H., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4304 · Cited by 259 · see citing works

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.054 · Cited by 246 · see citing works

The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non‐human primate model of Alzheimer's disease

Batista, A. F., Forny‐Germano, L., Clarke, J. R., Silva, N. M. L. E., Brito‐Moreira, J., Boehnke, S. E., Winterborn, A., Coe, B. C., Lablans, A., Vital, J. F. S., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5056 · Cited by 246 · see citing works

Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort

Wahlqvist, M. L., Lee, M., Hsu, C.-C., Chuang, S., Lee, J.-T., & Tsai, H.-N. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.03.010 · Cited by 233 · see citing works

A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients With Alzheimer Disease

Geldmacher, D. S., Fritsch, T., McClendon, M. J., & Landreth, G. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.229 · Cited by 221 · see citing works

Global, regional, and national burden of neurological disorders in 204 countries and territories worldwide

Huang, Y., Li, Y., Pan, H., & Han, L. (2023) · Journal of Global Health · doi:10.7189/jogh.13.04160 · Cited by 202 · see citing works

Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer’s disease

Park, J.-S., Kam, T.-I., Lee, S., Park, H., Oh, Y., Kwon, S.-H., Song, J.-J., Kim, D., Kim, H., Jhaldiyal, A., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01180-z · Cited by 192 · see citing works

A systematic review of meta-analyses that evaluate risk factors for dementia to evaluate the quantity, quality, and global representativeness of evidence

Anstey, K. J., Ee, N., Eramudugolla, R., Jagger, C., & Peters, R. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190181 · Cited by 187 · see citing works

Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence

Chow, H.-M., Shi, M., Cheng, A., Gao, Y., Chen, G., Song, X., So, R. W. L., Zhang, J., & Herrup, K. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0505-1 · Cited by 171 · see citing works

A Pilot Study of Exenatide Actions in Alzheimer’s Disease

Mullins, R. J., Mustapić, M., Chia, C. W., Carlson, O. D., Gulyani, S., Tran, J., Li, Y., Mattson, M. P., Resnick, S. M., Egan, J. M., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190913155950 · Cited by 160 · see citing works

PIOGLITAZONE IMPROVED COGNITION IN A PILOT STUDY ON PATIENTS WITH ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT WITH DIABETES MELLITUS

Hanyu, H., Sato, T., Kiuchi, A., Sakurai, H., & Iwamoto, T. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02067.x · Cited by 158 · see citing works

Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial

McGarry, A., Rosanbalm, S., Leinonen, M., Olanow, C. W., To, D., Bell, A., Lee, D., Chang, J., Dubow, J., Dhall, R., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00378-2 · Cited by 153 · see citing works

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

Olmo-García, M. I. D., & Merino-Torres, J. F. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4020492 · Cited by 144 · see citing works

α‐Synuclein real‐time quaking‐induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism

van Rumund, A., Green, A. J. E., Fairfoul, G., Esselink, R. A. J., Bloem, B. R., & Verbeek, M. M. (2019) · Annals of Neurology · doi:10.1002/ana.25447 · Cited by 138 · see citing works

Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease

Watson, K. T., Wroolie, T., Tong, G., Foland‐Ross, L. C., Frangou, S., Singh, M. K., McIntyre, R. S., Roat-Shumway, S., Myoraku, A., Reiss, A. L., et al. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.08.006 · Cited by 134 · see citing works

Insulin Resistance Promotes Parkinson’s Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling

Hong, C.-T., Chen, K.-Y., Wang, W., Chiu, J.-Y., Wu, D., Chao, T.-Y., Hu, C.-J., Chau, K.-Y., & Bamodu, O. (2020) · Cells · doi:10.3390/cells9030740 · Cited by 133 · see citing works

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer’s disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.

Burns, D. K., Alexander, R. C., Welsh-Bohmer, K. A., Culp, M., Chiang, C., O’Neil, J., Evans, R. M., Harrigan, P., Plassman, B. L., Burke, J. R., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00043-0 · Cited by 130 · see citing works

Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model

Qi, L., Ke, L., Liu, X., Liao, L., Ke, S., Liu, X., Wang, Y., Lin, X., Zhou, Y., Wu, L., et al. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.052 · Cited by 128 · see citing works

Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain

Zhao, L., Li, Z., Vong, J. S. L., Chen, X., Lai, H. M., Yan, L. Y. C., Huang, J., Sy, S. K. H., Tian, X. Y., Huang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18249-3 · Cited by 119 · see citing works

Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis‐related NLRP3 pathway

Song, S., Guo, R., Mehmood, A., Zhang, L., Yin, B., Yuan, C., Zhang, H., Guo, L., & Li, B. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13791 · Cited by 111 · see citing works

Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice

Li, Y., Bader, M., Tamargo, I. A., Rubovitch, V., Tweedie, D., Pick, C. G., & Greig, N. H. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13169 · Cited by 103 · see citing works

GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes

Wilbon, S. S., & Kolonin, M. G. (2023) · Cells · doi:10.3390/cells13010065 · Cited by 101 · see citing works

A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson′s disease by increasing expression of BNDF

Ji, C., Xue, G., Cao, L., Feng, P., Li, D., Li, L., Li, G., & Hölscher, C. (2015) · Brain Research · doi:10.1016/j.brainres.2015.09.035 · Cited by 101 · see citing works

Mechanism of metformin regulation in central nervous system: Progression and future perspectives

Cao, G., Gong, T., Du, Y., Wang, Y., Ge, T., & Liu, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113686 · Cited by 97 · see citing works

Subcutaneous Administration of Liraglutide Ameliorates Alzheimer-Associated Tau Hyperphosphorylation in Rats with Type 2 Diabetes1

Yang, Y., Zhang, J., Ma, D., Zhang, M., Hu, S., Shao, S., & Gong, C. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130491 · Cited by 92 · see citing works

The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy.

Hansen, H. H., Barkholt, P., Fabricius, K., Jelsing, J., Terwel, D., Pyke, C., Knudsen, L., & Vrang, N. (2016) · Brain Research · doi:10.1016/j.brainres.2015.12.052 · Cited by 92 · see citing works

The Neuroprotection of Liraglutide on Alzheimer-Like Learning and Memory Impairment by Modulating the Hyperphosphorylation of Tau and Neurofilament Proteins and Insulin Signaling Pathways in Mice

Xiong, H., Chen, Z., Wang, J., Song, J., Zhao, G., Shen, H., & Deng, Y. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130584 · Cited by 90 · see citing works

Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Reduces Alzheimer Disease-Associated Tau Hyperphosphorylation in the Hippocampus of Rats with Type 2 Diabetes

Xu, W., Yang, Y., Yuan, G., Zhu, W., Ma, D., & Hu, S. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000129 · Cited by 90 · see citing works

Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats

Candeias, E., Sebastião, I., Cardoso, S., Carvalho, C., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Duarte, A. I. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0622-3 · Cited by 88 · see citing works

Autocrine Interleukin-10 Mediates Glucagon-Like Peptide-1 Receptor-Induced Spinal Microglial β-Endorphin Expression

Wu, H., Tang, X.-Q., Mao, X.-F., & Wang, Y. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1799-17.2017 · Cited by 87 · see citing works

GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimer’s disease by regulating mitochondrial dysfunction via the cAMP/PKA pathway

Xie, Y., Zheng, J., Li, S., Li, H., Zhou, Y., Zheng, W., Zhang, M., Liu, L., & Chen, Z. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114578 · Cited by 87 · see citing works

Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals

Bomba, M., Ciavardelli, D., Silvestri, E., Canzoniero, L. M. T., Lattanzio, R., Chiappini, P. B. O., Piantelli, M., Ilio, C. D., Consoli, A., & Sensi, S. L. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.139 · Cited by 84 · see citing works

Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model

Lv, Y.-Q., Yuan, L., Sun, Y., Dou, H.-W., Su, J.-H., Hou, Z.-P., Li, J.-Y., & Li, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00288-z · Cited by 82 · see citing works

Activation of glucagon-like peptide-1 receptor in microglia attenuates neuroinflammation-induced glial scarring via rescuing Arf and Rho GAP adapter protein 3 expressions after nerve injury

Qian, Z., Chen, H., Xia, M., Chang, J., Li, X., Ye, S., Wu, S., Jiang, S., Bao, J.-P., Wang, B., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.68974 · Cited by 81 · see citing works

Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology

Holubová, M., Hrubá, L., Popelová, A., Bencze, M., Pražienková, V., Gengler, S., Kratochvílová, H., Haluzı́k, M., Železná, B., Kuneš, J., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.002 · Cited by 80 · see citing works

A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease

Jalewa, J., Sharma, M. K., Gengler, S., & Hölscher, C. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.02.013 · Cited by 79 · see citing works

Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5×FAD mouse model of Alzheimer’s disease

An, J., Zhou, Y., Zhang, M., Xie, Y., Ke, S., Liu, L., Pan, X., & Zhou, C. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111932 · Cited by 79 · see citing works

Activation of glucagon-like peptide-1 receptor ameliorates cognitive decline in type 2 diabetes mellitus through a metabolism-independent pathway

Li, Q., Jia, M., Yan, Z., Li, Q., Sun, F., He, C., Li, Y., Zhou, X., Zhang, H., Liu, X., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020734 · Cited by 77 · see citing works

Exendin-4 attenuates brain mitochondrial toxicity through PI3K/Akt-dependent pathway in amyloid beta (1–42)-induced cognitive deficit rats

Garabadu, D., & Verma, J. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.04.006 · Cited by 75 · see citing works

Early intervention with glucagon‐like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice

Ma, D., Chen, F., Xu, W., Yue, W., Yuan, G., & Yang, Y. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13248 · Cited by 73 · see citing works

Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study

Cheng, H., Zhang, Z., Zhang, B., Zhang, W., Wang, J., Ni, W., Miao, Y., Liu, J., & Bi, Y. (2022) · Diabetes Care · doi:10.2337/dc21-2064 · Cited by 71 · see citing works

A novel GLP‐1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease

Li, T., Jiao, J., Hölscher, C., Wu, M., Zhang, J., Tong, J., Dong, X., Qu, X., Cao, Y., Cai, H., et al. (2018) · Hippocampus · doi:10.1002/hipo.22837 · Cited by 69 · see citing works

GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimer's disease models through the Akt/GSK-3β/β-catenin signaling

Wang, Y., Chen, S., Zheng, X., Chen, S., Yao, W., & Gao, X. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.048 · Cited by 67 · see citing works

Liraglutide ameliorates cognitive decline by promoting autophagy via the AMP-activated protein kinase/mammalian target of rapamycin pathway in a streptozotocin-induced mouse model of diabetes

Kong, F., Wu, J., Sun, S., Ma, L., & Zhou, J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.001 · Cited by 66 · see citing works

Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease

Bomba, M., Granzotto, A., Castelli, V., ONOFRJ, M. C., Lattanzio, R., Cimini, A., & Sensi, S. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-190237 · Cited by 64 · see citing works

Diabetes: a tipping point in neurodegenerative diseases

Santiago, J. A., Karthikeyan, M., Lackey, M., Villavicencio, D., & Potashkin, J. A. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.09.005 · Cited by 64 · see citing works

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease

Hansen, H. H., Fabricius, K., Barkholt, P., Wismann, P., Schlumberger, C., Jelsing, J., Terwel, D., Termont, A., Pyke, C., Knudsen, L. B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158205 · Cited by 63 · see citing works

Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects?

Femminella, G. D., Livingston, N. R., Raza, S., van der Doef, T. F., Frangou, E., Love, S., Busza, G., Calsolaro, V., Carver, S., Holmes, C., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00784-w · Cited by 61 · see citing works

Metformin therapy and cognitive dysfunction in patients with type 2 diabetes

Zhang, Q., Li, W., Liu, Z., Zhang, H., Ba, Y., & Zhang, R. (2020) · Medicine · doi:10.1097/md.0000000000019378 · Cited by 58 · see citing works

Neuroprotective effects of liraglutide against inflammation through the AMPK/NF-κB pathway in a mouse model of Parkinson’s disease

Cao, B., Zhang, Y., Chen, J., Wu, P., Dong, Y., & Wang, Y. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00879-1 · Cited by 57 · see citing works

Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro

An, F.-M., Chen, S., Xu, Z., Yin, L., Wang, Y., Liu, A.-R., Yao, W.-B., & Gao, X.-D. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.023 · Cited by 55 · see citing works

GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art

Granata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac069 · Cited by 54 · see citing works

Association between Parkinson’s Disease and Diabetes Mellitus: From Epidemiology, Pathophysiology and Prevention to Treatment

Yu, H., Sun, T., He, X., Wang, Z., Zhao, K., An, J., Wen, L., Li, J., Li, W., & Feng, J. (2022) · Aging and Disease · doi:10.14336/ad.2022.0325 · Cited by 51 · see citing works

Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway

Kang, X., Wang, D., Zhang, L., Huang, T., Liu, S., Feng, X., Guo, Y., Zhang, Z., Wang, Z., Ren, H., et al. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00718-2 · Cited by 49 · see citing works

Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway

Wang, M., Huang, Y., Zhang, G.-P., Mao, L., Xia, Y., Mei, Y.-W., & Hu, B. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.025 · Cited by 48 · see citing works

The metabolite GLP‐1 (9‐36) is neuroprotective and anti‐inflammatory in cellular models of neurodegeneration

Li, Y., Glotfelty, E. J., Karlsson, T. E., Fortuno, L. V., Harvey, B. K., & Greig, N. H. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15521 · Cited by 47 · see citing works

Liraglutide prevents beta-amyloid-induced neurotoxicity in SH-SY5Y cells via a PI3K-dependent signaling pathway

Liu, X., Wang, L.-X., Chen, Z., & Liu, L. (2016) · Neurological Research · doi:10.1080/01616412.2016.1145914 · Cited by 45 · see citing works

The role of GLP-1 receptor agonists in managing type 2 diabetes

Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45 · see citing works

Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials

Malpetti, M., Joie, R. L., & Rabinovici, G. D. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263694 · Cited by 45 · see citing works

The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis

Yajima, T., Yajima, K., Takahashi, H., & Yasuda, K. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.05.018 · Cited by 45 · see citing works

Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner

Li, Z., Chen, X., Vong, J. S. L., Zhao, L., Huang, J., Yan, L. Y. C., Ip, B., Wing, Y. K., Lai, H.-M., Mok, V. C. T., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02208-9 · Cited by 42 · see citing works

Inhibiting receptor for advanced glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE induced neuronal apoptosis

Chen, S., Yin, L., Zheng, X., An, F.-M., Liu, A., Wang, Y., Yao, W., & Gao, X. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.12.007 · Cited by 42 · see citing works

Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes

Tang, X., Brinton, R. D., Chen, Z., Farland, L. V., Klimentidis, Y. C., Migrino, R. Q., Reaven, P. D., Rodgers, K. E., & Zhou, J. J. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002894 · Cited by 38 · see citing works

Combination of Insulin with a GLP1 Agonist Is Associated with Better Memory and Normal Expression of Insulin Receptor Pathway Genes in a Mouse Model of Alzheimer’s Disease

Robinson, A., Lubitz, I., Atrakchi, D., Licht-Murava, A., Katsel, P., LeRoith, D., Zaltsman, S. L., Haroutunian, V. H., & Beeri, M. S. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-1257-9 · Cited by 37 · see citing works

Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-β peptide-induced impairment of spatial learning and memory in rats

Jia, X.-T., Ye-Tian, Yuanli, Zhang, G., Liu, Z., Di, Z., Ying, X., Yan, F., Song, E., Qi, J., et al. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.03.016 · Cited by 36 · see citing works

Emerging Pathophysiological Mechanisms Linking Diabetes Mellitus and Alzheimer’s Disease: An Old Wine in a New Bottle

Patel, V. N., Chorawala, M. R., Shah, M. B., Shah, K. C., Dave, B. P., Shah, M. P., & Patel, T. M. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220021 · Cited by 36 · see citing works

Thiazolidinedione use is associated with reduced risk of Parkinson’s disease in patients with diabetes: a meta-analysis of real-world evidence

Hussain, S., Singh, A., Baxi, H., Taylor, B. V., Burgess, J., & Antony, B. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04494-3 · Cited by 29 · see citing works

Neurotrophic and neuroprotective properties of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and RhoA

Tsukamoto, M., Niimi, N., Sango, K., Takaku, S., Kanazawa, Y., & Utsunomiya, K. (2015) · Histochemistry and Cell Biology · doi:10.1007/s00418-015-1333-3 · Cited by 28 · see citing works

Exendin-4 improves long-term potentiation and neuronal dendritic growth in vivo and in vitro obesity condition

Wang, M., Yoon, G., Song, J., & Jo, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-87809-4 · Cited by 27 · see citing works

Semaglutide Protects against 6‐OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress

Liu, D.-X., Zhao, C.-S., Wei, X., Ma, Y.-P., & Wu, J.-K. (2022) · Parkinson s Disease · doi:10.1155/2022/6813017 · Cited by 27 · see citing works

A New Approach to the Development of Disease‐Modifying Therapies for PD ; Fighting Another Pandemic

Kieburtz, K. D., Katz, R. G., McGarry, A. J., & Olanow, C. W. (2020) · Movement Disorders · doi:10.1002/mds.28310 · Cited by 26 · see citing works

Thiazolidinedione use and risk of Parkinson’s disease in patients with type 2 diabetes mellitus

Zhao, H.-Y., Zhuo, L., Sun, Y., Shen, P., Lin, H., & Zhan, S. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00406-8 · Cited by 25 · see citing works

Exendin-4 antagonizes Aβ1-42-induced suppression of long-term potentiation by regulating intracellular calcium homeostasis in rat hippocampal neurons

Wang, X., Wang, L., Jiang, R., Yuan, Y., Yu, Q., & Li, Y. (2015) · Brain Research · doi:10.1016/j.brainres.2015.09.015 · Cited by 23 · see citing works

A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice

Wang, Z.-J., Han, Y., Zhao, F., Yang, G., Yuan, L., Cai, H.-Y., Yang, J., Hölscher, C., Qi, J., & Wu, M. (2019) · Hormones and Behavior · doi:10.1016/j.yhbeh.2019.104640 · Cited by 23 · see citing works

Metformin and the risk of neurodegenerative diseases in patients with diabetes: A meta‐analysis of population‐based cohort studies

Zhang, Y., Zhang, Y., Shi, X., Han, J., Lin, B., Peng, W., Mei, Z., & Yang, L. (2022) · Diabetic Medicine · doi:10.1111/dme.14821 · Cited by 22 · see citing works

Related expressional change of HIF-1α to the neuroprotective activity of exendin-4 in transient global ischemia

Jin, J., Kang, H.-M., Jung, J., Jeong, J.-W., & Park, C. (2014) · NeuroReport · doi:10.1097/wnr.0000000000000046 · Cited by 21 · see citing works

Expression of GLP-1 receptors in insulin-containing interneurons of rat cerebral cortex

Csajbók, É., Kocsis, Á. K., Faragó, N., Furdan, S., Kovács, B., Lovas, S., Molnár, G., Likó, I., Zvara, Á., Puskás, L. G., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4803-z · Cited by 19 · see citing works

Accelerated amyloid angiopathy and related vascular alterations in a mixed murine model of Alzheimer´s disease and type two diabetes

Vargas-Soria, M., Ramos‐Rodríguez, J. J., del Marco, À., Hierro‐Bujalance, C., Carranza-Naval, M. J., Calvo-Rodríguez, M., van Veluw, S. J., Stitt, A. W., Simó, R., Bacskai, B. J., et al. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00380-6 · Cited by 19 · see citing works

Care challenges of home health patients living with dementia: a pathway forward with palliative care

Cole, C. S., Dafoe, A., Tietbohl, C. K., Jordan, S., Huebschmann, A. G., Lum, H. D., & Jones, C. D. (2023) · BMC Palliative Care · doi:10.1186/s12904-023-01247-9 · Cited by 19 · see citing works

The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study

Kim, W. J., Noh, J. H., Han, K., & Park, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201535 · Cited by 16 · see citing works

The Antidiabetic Drug Liraglutide Minimizes the Non-Cholinergic Neurotoxicity of the Pesticide Mipafox in SH-SY5Y Cells

Fernandes, L. S., dos Santos, N. A. G., Emerick, G. L., & dos Santos, A. C. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9941-z · Cited by 9 · see citing works

Amyloid antibody therapy for early-stage Alzheimer’s disease: a critical review of three recent trials

Guiloff, A. E., & Rudge, P. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12361-w · Cited by 8 · see citing works

A look back at the prodromal findings in Parkinson’s disease

Ahadiat, S.-A., & Hosseinian, Z. (2023) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-023-01143-5 · Cited by 3 · see citing works

Diabetes and its complications: molecular mechanisms, prevention and treatment

Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80 · see citing works

The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health

Qassab, M. A., Mneimneh, M., Jradi, A., Derbas, B., Dabboussi, D., Baini, J. K., Katrib, N., Chaarani, N., Attieh, P., Kanaan, A., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040285 · Cited by 52 · see citing works

Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity

Lin, H.-T., Tsai, Y.-F., Liao, P.-L., & Wei, J. C.-C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.21016 · Cited by 43 · see citing works

Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders

Giorgi, R. D., Ghenciulescu, A., Yotter, C. N., Taquet, M., & Koychev, I. G. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-335593 · Cited by 39 · see citing works

Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)

Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 46 · see citing works

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities

Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 34 · see citing works

Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications

Kuthati, Y., Davuluri, V. N. G., & Wong, C. (2025) · Biomolecules · doi:10.3390/biom15050622 · Cited by 29 · see citing works

Multifunctional selenium-doped carbon dots for modulating Alzheimer's disease related toxic ions, inhibiting amyloid aggregation and scavenging reactive oxygen species

Shao, X., Fan, T., Yan, C., Cao, X., Wang, C., Wang, X., Guan, P., Li, F., & Hu, X. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139333 · Cited by 18 · see citing works

Linking Metabolic Syndrome to Neurodegeneration Mechanisms and Potential Treatments

Džidić-Krivić, A., Fajkić, A., Farhat, E. K., Lekić, L., Ejubović, A. J., Vukas, S. K., Ejubović, M., Lepara, O., & Sher, E. K. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04947-w · Cited by 18 · see citing works

Unravelling Shared Pathways Linking Metabolic Syndrome, Mild Cognitive Impairment, Dementia, and Sarcopenia

Ceccarelli, D. C., & Solerte, S. B. (2025) · Metabolites · doi:10.3390/metabo15030159 · Cited by 17 · see citing works

Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases

Raut, S., & Cucullo, L. (2025) · Antioxidants · doi:10.3390/antiox14121490 · Cited by 16 · see citing works

GLP-1 receptor agonists in Alzheimer’s and Parkinson’s disease: endocrine pathways, clinical evidence, and future directions

Gandhi, A., & Parhizgar, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1708565 · Cited by 13 · see citing works

IUPHAR review: From gut to brain: The role of gut dysbiosis, bacterial amyloids, and metabolic disease in Alzheimer’s disease

Inan, S., Wilson, R. P., & Tükel, Ç. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107693 · Cited by 13 · see citing works

Psychotropic effects of GLP-1R agonists

Bucciarelli, L. G., Cimino, V., Dell’Osso, B. M., & Fiorina, P. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108036 · Cited by 13 · see citing works

Pathology and Treatments of Alzheimer’s Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes

Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2024) · Molecules · doi:10.3390/molecules29245936 · Cited by 11 · see citing works

Diabetes mellitus in the elderly: clinical and epidemiological characteristics of the all-Russian cohort of diabetic patients over 65 years

Shestakova, M. V., Vikulova, O. K., Zheleznyakova, A. V., Kutakova, D. V., Исаков, М. А., & Mokrysheva, N. G. (2025) · Diabetes Mellitus · doi:10.14341/dm13261 · Cited by 10 · see citing works

GLP-1R in diabetes mellitus: from basic discovery to therapeutics development

Li, S., Huang, N., Wang, M., Huang, W., Luo, Y., & Huang, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1610512 · Cited by 10 · see citing works

Breaking the vicious cycle: bitter compounds targeting metabolic defects and inflammation in Alzheimer’s disease

Wu, H., He, L., & Dai, L. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00166.2025 · Cited by 9 · see citing works

GLP-1 Receptor Agonists and Noncardiometabolic Outcomes

Yang, K., Liu, C., Guo, Q., & Li, Y. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.4722 · Cited by 10 · see citing works

Therapeutic efficacy of 4-hydroxyisoleucine in experimental rat model of demyelination: Neuroprotection through IGF-1 and GLP-1 level restoration

Khan, Z., Mehan, S., & Gupta, G. D. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157448 · Cited by 8 · see citing works

GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks

Ilias, Ι., Zabulienė, L., & Rizzo, M. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1530811 · Cited by 8 · see citing works

Associations between eight anthropometric indices and Parkinson’s disease: a nationwide population-based study

Hu, W., Zhang, Y., & Liu, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1621658 · Cited by 7 · see citing works

GLP-1 receptor agonist liraglutide facilitates rotator cuff healing by reducing tendon cell inflammation and endoplasmic reticulum stress through the GLP-1R-AMPK/SIRT1 pathway

Zhang, X., Chi, R., Xu, J., Meng, C., Wang, Z., Ruo, W., Xin, F., Xu, T., Guo, F., Wang, G., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116010 · Cited by 7 · see citing works

Targeting of the PI3K/AKT/mTOR signaling pathway in the neurovascular interface in both Alzheimer's disease and atherosclerosis: The potential nexus

Alameen, A. A. M., Al‐kuraishy, H. M., Al-Gareeb, A. I., Shokr, M. M., & Batiha, G. E. (2026) · Microvascular Research · doi:10.1016/j.mvr.2026.104947 · Cited by 6 · see citing works

Anti-inflammatory effects of GLP1-RA drugs

Quintana, L., Tabaza, N., Kurt, B., & Kahles, F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag218 · Cited by 6 · see citing works

Association of SGLT2 inhibitors and GLP-1 receptor agonists with the risk of Parkinson’s disease in patients with type 2 diabetes: A propensity score–matched cohort study with meta-analysis

Yeh, J.-A., Lin, S., Liu, Y., Hsu, J.-Z., Huang, A. H., Munir, K. M., Peng, C. C., Loh, C., & Huang, H. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112914 · Cited by 6 · see citing works

GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review

Orozco, M. P., Rivadeneira, V. V., & León-Rojas, J. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412163 · Cited by 7 · see citing works

Targeting glucose transporters in parkinson’s disease: a novel metabolic approach for disease modification

Singh, G., Ansari, S., & Aran, K. R. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01697-5 · Cited by 5 · see citing works

Mitophagy in neurodegeneration: crosstalk between PRKN/parkin-dependent and PRKN-independent pathways

Rasmussen, L. K., Moreira, D. G., Okarmus, J., Simonsen, A., & Meyer, M. (2026) · Autophagy · doi:10.1080/15548627.2026.2711596 · Cited by 4 · see citing works

Long‐term delirium and survival outcomes in patients treated with GLP ‐1 receptor agonists versus metformin in type 2 diabetes: A population‐based cohort study

Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16434 · Cited by 5 · see citing works

Immunological effects of GLP-1 analogs on female reproduction: Therapeutic perspectives for infertility and recurrent pregnancy loss

Tavares, A. C. M., Martins, M. Y. M., de Souza, G. F., Lima, E. M., Rocha, C. A., de Souza, L. C., Simões, J. M. L., ARAÚJO, N. O. D., & Cavalcante, M. B. (2025) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2025.104538 · Cited by 6 · see citing works

A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait

Alali, S., Alotaibi, W. S., Ashodian, K., Achour, N., Almulla, A., & Mutlaq, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1590379 · Cited by 4 · see citing works

Modulating reward circuits through GLP-1 signaling: implications for behavioral and substance addictions

Martinelli, S., & Petrucciani, N. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06989-3 · Cited by 3 · see citing works

GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD

Lee, W.-T., Jing Tong, W. A. N. G., Tsai, M., & Fang, Y. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag032 · Cited by 3 · see citing works

Neuroprotective Role of Pioglitazone Against LPS-Induced Neuroinflammation in Wistar Rats, Targeting Superoxide Dismutase, Lipid Peroxidation and Cognitive Changes

Blossom, V., Ullal, S. D., Rai, R., Hegde, A., Rai, S., & Anita Sherly, A. (2026) · Oxygen · doi:10.3390/oxygen6020006 · Cited by 3 · see citing works

Precision prevention for neurodegenerative diseases: lessons learnt from Alzheimer’s disease translated into perspectives for Parkinson’s disease

Béchet, S., Leonard, M. V., Ademola, E., Fritz, J. V., & Krüger, R. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03090-z · Cited by 2 · see citing works

Exercise as Chronotherapy: Regulating Circadian Rhythms to Alleviate Symptoms in Parkinson’s Disease

Li, J., Liu, T., & Wei, J. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00844 · Cited by 2 · see citing works

Molecular mechanisms underlying Parkinson’s disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy

Juthi, S. S., Ansari, P., Ahmed, M. F., Khan, J. T., Seidel, V., Kumar, S., Kumari, R., McKillop, A. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1798309 · Cited by 2 · see citing works

Integrating GLP-1 Receptor Agonists into Modern Stroke Prevention: Evidence, Mechanisms, and Clinical Consideration—A Narrative Review

Khan, S., Herbst, W., Tajrishi, F. Z., Notani, S., Knight, A., Jamil, Z., & Ferdinand, K. C. (2026) · Biomedicines · doi:10.3390/biomedicines14040743 · Cited by 3 · see citing works

Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum — Mechanisms, evidence, and future directions

Dahshan, A., Khalil, M. I. M., El-Jaafary, S. I., & Yamani, A. (2026) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2026.100461 · Cited by 2 · see citing works

Research progress and future prospects of small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs)

Tu, Y., & Yu, H. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.99 · Cited by 2 · see citing works

Dapagliflozin restores odour‐induced functional integration of primary olfactory cortex circuit but not olfactory‐related regional brain activation in patients with type 2 diabetes: A 16‐week randomised comparative study

Li, X., Zhang, Y., Bi, Y., Lu, J., Zhang, Z., Ji, C., Zhang, B., Li, Q., Wang, S., Chen, J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70132 · Cited by 1 · see citing works

Narrative review on glucagon-like peptide-1 receptor agonists and late-life depression: A new frontier in geriatric psychiatry?

Marano, G., Rossi, S., Lisci, F. M., Traversi, G., Mazza, O., Claro, A. E., Pola, R., Pitocco, D., Sani, G., Gaetani, E., et al. (2025) · Aging advances. · doi:10.4103/agingadv.agingadv-d-25-00027 · Cited by 1 · see citing works

Exploring the intersection of Alzheimer's disease and comorbidities: a review of the interplay between multiple chronic conditions

Khan, S., Imam, A., Singh, S., Ahmed, A., Hassan, M. I., Shahid, M., Athar, F., & Islam, A. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168190 · Cited by 1 · see citing works

Targeting metabolic dysfunction in amyotrophic lateral sclerosis: therapeutic potential of GLP-1 receptor agonists

Helal, M. M., Almosilhy, N. A., Abo‐elnour, D. E., Jaffal, R., Allam, E. G., Almosilhy, M. A., Batarseh, S. F., & Meshref, M. M. (2026) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2026.2627901 · Cited by 2 · see citing works

Efficacy and safety of GLP-1 receptor agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized clinical trials

Mendonça, M. F., Interaminense, A. C., Barros, G. S. T. D. R., Rabelo, L. A., de Oliveira, P. G. G., Sales, R. F., Lyra, A. M. V. D. C., & Silva, H. R. D. S. E. [. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09084-3 · Cited by 1 · see citing works

Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy

Kennedy, S., Thomas, J., Darcy, S., Odia, I., Kamdar, D., Pereira, L., Scarola, D., Miles, B., Frank, D. K., Taneja, C., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1834606 · Cited by 1 · see citing works

Is amyloid beta peptide a driver of inflammaging?

Kechko, O. I., Moskalev, A. A., Franceschi, C., Mitkevich, V. A., & Makarov, A. А. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103280 · Cited by 1 · see citing works

Complement 3a Receptor mediates high fat diet induced hypothalamic accumulation of lipid associated microglia to regulate neuroinflammation and obesityPreprint

Pallais, J. P., Razzoli, M., Rodriguez, P., McGonigle, S., Daugherty, A. L., Hillman, H., Verteramo, L., Schrank, P. R., Parthiban, P., Chang, X., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.18.719397 · Cited by 1 · see citing works

Estimated glucose disposal rate is correlated with decreased parkinson’s disease: a population-based study

Hu, W., Liu, H., Zhang, Y., & Liu, H. (2025) · Acta Neurologica Belgica · doi:10.1007/s13760-025-02845-5

Prospective Assessment of Alzheimer's Disease-Like Hypometabolism Pattern in the Brain of Diabetics in Contrast to Non-diabetics on Positron Emission Tomography-Computed Tomography Images Using Fluorodeoxyglucose in India

Kumar, P., Lele, V. R., & Akhtar, M. J. (2025) · Cureus · doi:10.7759/cureus.89682

CauReL: Dynamic Counterfactual Learning for Precision Drug Repurposing in Alzheimer's DiseasePreprint

Wang, Y., Zhou, M., Tang, Z., Xiong, C., Asken, B. M., Yang, B., Su, J., Zhou, X., & Song, Q. (2025) · Research Square · doi:10.21203/rs.3.rs-8206648/v1

Harnessing the gut-brain axis in the treatment of type 2 diabetes mellitus and obesity

Kotucha, K., Kapłon, K., Moś, M., Fiegler-Rudol, J., Pietryszyn-Bilińska, A., Dynarowicz, K., Aebisher, D., Wiench, R., & Kawczyk‐Krupka, A. (2025) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2025.4.24

Treatment of type 2 diabetes among medicare beneficiaries with and without alzheimer’s disease: A retrospective cohort study

Wang, Y., Alexander, G. C., & Mehta, H. B. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01838-8

Semaglutide exerts neuroprotective effects by blocking the interleukin-17/NOD-like receptor family pyrin domain containing 3-mediated neuroinflammation pathway after traumatic brain injury

Zhang, B., Kong, L., Wang, Y., He, W., Yang, M., Zhang, X., Chen, X., Zhang, Y., Liu, B., Bai, M., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00990

GLP-1 and the brain’s powerhouse: a new perspective on the role of mitochondria in neuroprotection

Dasgupta, T., Bhayani, H., Ghoshdastidar, K., Viswanathan, K., & Jain, M. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01839-3

Current hypothesis for AD progression

Kim, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45844-6.00016-0

GLP-1 agonist and neuroprotection in Stroke and Parkinson’s disease: A systematic review

Parekh, D. S., Kudaiarov, D., Inban, P., Agrawal, A., Prajjwal, P., & Tariq, H. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102151

Sleeve gastrectomy improves cognition by enhancing central ERK/CREB/BDNF pathway through increased GIP secretion

Wei, Z., Yang, J., Qiao, Y., Wang, S., Cai, Y., & Gao, L. (2026) · iScience · doi:10.1016/j.isci.2026.116292

Current and emerging drugs for Parkinson’s disease: mechanisms, clinical evidence, and future directions

Yang, F. Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1805370

Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: a bibliometric analysis of global research trends and research hotspots from 2006 to 2025

Bi, Q., Zhang, L., Zhang, J. H., (91924), X. W., Zuo, C., Zhao, S., Wang, Z. L., Zhao, Z., & Wan, H. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05635-9

GLP-1 receptor agonists in Parkinson’s disease: a meta-analysis revealing motor benefit and highlighting mood improvement

Chen, Y., Zhang, Z. K., Liu, Z., Lv, T., Ye, M., Yan, J., & Zhang, M. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1858507

Research hotspots and trends of GLP-1 receptor agonists in the treatment of Parkinson’s disease: a bibliometric analysis

Yu, T., Mai, Q., Wang, Q., Pan, M., Xiong, Y., Kuang, L., & Liu, H. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1894856

Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions

Arvez, M. J. A., Wade, S., Goordeen, D., Ilomäki, J., Cross, A. J., Langiu, M., & Tan, G. S. Q. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70414

Impact of glucagon-like peptide-1 receptor agonists on bone metabolism

Vadini, V., Duan, D., & Moseley, K. F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag323 · Cited by 1 · see citing works

Glucose-Lowering Therapies and Cognitive Decline: From Molecular Mechanisms to Clinical Evidence and Future Perspectives

Grasso, M., Maggio, V., Caraci, F., & Rizzo, M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03760-8 · Cited by 1 · see citing works

Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study

Nasir, A. B., Kilani, Y., Aldiabat, M., Abdelghany, O., Hafez, Y., Desai, N., Madi, M. Y., Wade, F. G., Qureshi, K., Frey, L. J., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0356138

Glycolytic Reprogramming in Parkinson's Disease: From Bioenergetic Crosstalk to Therapeutic Modulation

Yi, Y., Chen, C., He, Y., Yu-zhou, S., Cheng, R., Liu, M., Liu, Z., & Zhang, X. (2026) · Medicinal Research Reviews · doi:10.1002/med.70103

BEYOND GLYCEMIC CONTROL AND WEIGHT REDUCTION: PLEIOTROPIC EFFECTS OF GLP-1 RECEPTOR AGONISTS ON HUMAN PHYSIOLOGY - A NARRATIVE REVIEW

Król, M., Woźniak, A., Straszewska, A., Sobantka, P., Mokrzecki, S., Mamach, A., Aleksandrowicz, K., Grodzka, Z., Meszka, M., Bełc, E., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.6208

Gut microbiota as a modulator of HDAC: insights into Alzheimer’s disease treatment

Verma, E., Mishra, S., Chellammal, H. S. J., Khandige, P. S., & Gasmi, A. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00897-9

Heart Failure and Neurocognitive Disorders: A Narrative Review

Lin, S., Wang, Q., & Cao, J. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.126.014265

Heterogeneous vascular contributions to cognitive impairment and dementia

Yamashita, T., Hu, C.-J., & Alkayed, N. J. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.116043

GLP-1 receptor agonists as potential disease-modifying agents in Parkinson’s and Alzheimer’s disease: mechanisms, clinical trial evidence, and the neuroprotection horizon

Alsharif, M., Shrebaty, O., Aloudah, M. A., Alqahtani, M., AlOubili, R. S., Ahmed, M. J., AlBani, B., & Bana, A. E. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1969490 · Cited by 1 · see citing works

Efsubaglutide Alfa: A Comprehensive Pharmacological Review

Zheng, H., Yan, R., Jiang, F., Li, Y., Prud’homme, G. J., & WANG, Q. (2026) · Clinical Pharmacokinetics · doi:10.1007/s40262-026-01713-6

From gut microbiome to aging brain: Butyrate as a neurogeroscience effector

Mitrea, L., Calinoiu, L.-F., Martau, G.-A., Teleky, B.-E., Cocean, A.-M., Odocheanu, R., Stefanescu, B.-E., & Vodnar, D.-C. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.107037

Combined melatonin and edaravone therapy attenuates methylmercury-induced amyotrophic lateral sclerosis-like neurodegeneration through GLP-1 modulation and myelin preservation

Raina, G. S., Mehan, S., & Gupta, G. D. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-06009-x

Gut–brain axis: new targets and novel mechanisms of traditional Chinese medicines and natural products interventions in neurodegenerative diseases

汪, 矛., Wang, Y., Jia, Z., Fu, Y., Luo, Y., & 孙, 晓. (2026) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/csb-2026-0978

EXPANDING THERAPEUTIC HORIZONS OF GLP-1 RECEPTOR AGONISTS: FROM METABOLIC REGULATION TO NEUROPROTECTION IN ALZHEIMER’S DISEASE AND ADDICTION DISORDERS – A COMPREHENSIVE REVIEW

Reczka, K., Zalewska, Z., Szymkowiak, J., & Woźniak, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(52).2026.6289

Introduction to neuro-immunometabolism: Connecting immune and nervous systems

Jindal, A., Goel, F., Kumar, A., Garg, V. K., Singh, P., Nand, S., & Yadav, D. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44253-7.00009-6

GLP-1 receptor agonists in Alzheimer’s and Parkinson’s disease: endocrine pathways, clinical evidence, and future directions

Gandhi, A., & Parhizgar, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1708565 · Cited by 13 · see citing works

The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer’s and Parkinson’s Disease: A Literature Review of Clinical Trials

Pilśniak, J., Węgrzynek‐Gallina, J., Bednarczyk, B., Buczek, A., Pilśniak, A., Chmiela, T., Jarosińska, A., Siuda, J. S., & Holecki, M. T. (2025) · Life · doi:10.3390/life15121893

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases

Cheng, D., Yang, S., Zhao, X., & Wang, G. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s348055 · Cited by 84 · see citing works

Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders

Sabbagh, M. N., Cummings, J. L., Ballard, C. G., van der Flier, W. M., Heneka, M. T., Holst, J. J., Knudsen, L. B., Salloway, S., Tansey, M. G., & Drucker, D. J. (2025) · Nature Aging · doi:10.1038/s43587-025-01029-3 · Cited by 14 · see citing works

Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases

Chen, S., Chuang, Y., Lin, T., & Yang, J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175439 · Cited by 66 · see citing works